Shots: The approval is based on P-III MAIA study assessing Darzalex + lenalidomide + dexamethasone (Rd) vs Rd as monothx. in 737 patients with newly diagnosed multiple myeloma who are ineligible for high-dose chemotherapy and ASCT aged 45-90 yrs. The P-III MAIA study results: 44% reduction in risk of disease progression; CR (48% vs 25%); […]Read More
Shots: Dicerna to receive $200M up front and up to $1.47B development, regulatory and commercial milestones and royalties based on the sales of DCR-HBVS. Roche to get WW license to develop & commercialize DCR-HBVS utilizing Dicerna’s GalXC RNAi platform technology Dicerna holds an option to co-fund global development of DCR-HBVS, which if exercised, Dicerna will […]Read More
Shots: The companies together formed a multi-faceted global strategic alliance which combines the technologies of both the companies to deliver a new generation of medical functionality to wearable devices Huami will utilize AliveCor’s Intelligent, medical grade, heart care platform in its smart watches and heart trackers and will provide AliveCor’s AI driven subscription services and […]Read More
Shots: J&J Vision launches TECNIS Eyhance monofocal IOL to provide the advance solution for patients who have undergone cataract removal surgery The launch of monofocal IOL aims to change the trajectory of eye health and to raise the standards of eye care for post-cataract surgery patients in India and around the world The TECNIS Eyhance […]Read More
Shots: The US FDA’s Center for Devices and Radiological Health has granted breakthrough device designation for Shreis’ Cytotron, invented by Dr. Rajah Vijay Kumar in Bengaluru, India, indicated for the treatment of solid tumors of the breast, liver, and pancreas Shreis is actively collaborating with other companies for the clinical studies of Cytotron in the […]Read More
Shots: Pandion to receive up to $45M as upfront and payments for research and preclinical activities, ~$750M as development and commercial milestone and royalties on global sales of the therapies developed via collaboration Pandion to be responsible for drug designing and discovery of bispecific therapies utilizing its modular immune effector and tissue tether platform while […]Read More
Shots: The companies collaborated to explore developing PDTs for the treatment of patients with selected indications within the gastrointestinal space The focus of the agreement is to merge Pear’s expertise in PDTs with Ironwood’s GI franchise and clinical expertise and to expand Pear’s portfolio outside the central nervous system The collaboration will provide an opportunity […]Read More
Shots: The FDA’s approval is based on NDA submitted under the 505(b)(2) filing pathway and contain data from P-III EVOLVE-MS-1 study assessing Vumerity in patients with relapsing-remitting MS In Nov’2017, Biogen and Alkermes collaborated to develop & commercialize Vumerity under which Alkermes to receive $150M and royalties on WW sales of Vumerity for the 5yrs. […]Read More
Shots: Ubiquigent to receive up front, option exercise fee and milestone payment. Leo Pharma to get an option to access two novel therapies The partnership will strengthen Leo Pharma’s research capabilities and disease understanding and extending its expertise in medical dermatology worldwide The option agreement follows 2018 agreement signed b/w Ubiquigent and LEO Pharma to […]Read More
Shots: The partial hold on clinical study for intrathecal administration of AVXS-101 follows the findings of the pre-clinical study demonstrated dorsal root ganglia (DRG) mononuclear cell inflammation accompanied by neuronal cell body degeneration or loss The partial hold does not have any impact on marketed Zolgensma or AVXS-101 (IV) clinical studies and will remain available […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
